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Abstract 
 
Background: Pleomorphic and Florid Lobular carcinoma in situ (P/F LCIS) are rare variants of 
LCIS, the exact nature of which is still debated. 
Aim: To collect a large series of P/F LCIS diagnosed on preoperative biopsies and evaluate their 
association with invasive carcinoma and high grade duct carcinoma in situ (DCIS). Data obtained 
were compared with those reported in the literature. 
Methods: A multi-institutional series of P/F LCIS was retrieved. All cases were diagnosed on pre- 
operative biopsies, which was followed by an open surgical excision. Data on post-operative 
histopathology were available. A literature review was performed. 
Results: A total of 117 cases were collected; invasive carcinoma and/or DCIS was present in 78/117 
cases (66.7%). Seventy cases of P/F LCIS were pure on biopsy and 31 of these showed  pathological 
upgrade in post-surgical specimens. Pre-operative biopsy accuracy was 47/78 (60.3%); pre-operative 
biopsy underestimation of cancer was 31/78 (39,7.%). In the literature review papers, invasive 
carcinoma or DCIS was associated with 274 of 418 (65.5%) cases of P/F LCIS. Pre- operative biopsy 
accuracy was 66% (181/274) whereas pre-operative biopsy underestimation of cancer was 33.9% 
(93/274). 
Conclusions: The data presented here indicate that P/F LCIS is frequently associated with invasive 
carcinoma or high grade DCIS and that pre-operative biopsy is associated with an underestimation of 
malignancy. Open surgery is indicated when P/F LCIS is diagnosed pre-operatively. 
 
 
Key words: Lobular carcinoma in situ, Pleomorphic lobular carcinoma in situ; Florid lobular 
carcinoma in situ; pre-operative biopsy; breast cancer screening. 
 
 
Highlights: 
 
 
• Pleomorphic and lobular carcinoma in situ (P/F LCIS) are associated with invasive 
carcinoma and / or high nuclear grade in situ duct carcinoma in more than 60% of the cases. 
• Pre-operative biopsies of P/F LCIS can frequently under-estimate the presence of invasive 
carcinoma. 
• Open surgery with clear resection margins is recommended in cases of P/F LCIS. 
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Introduction 
 
Lobular carcinoma in situ (LCIS), classical variant (C-LCIS), is considered a non-obligate precursor 
of invasive carcinoma1. The risk of developing an invasive carcinoma in patients affected by C- LCIS 
varies from 8 to 10 times relative risk when compared to the general population2. When C- LCIS is 
present in pre-operative biopsies, the risk of upgrading to invasive carcinoma varies from 8 to 40%, 
greatly dependent on the related mammographic findings2. These data suggest that surgical excision 
of C-LCIS may be necessary only if mammographically detected anomalies are not completely 
removed during the pre-operative procedures2. In addition to C-LCIS, LCIS may present in variant 
forms, as Florid LCIS (F-LCIS) and Pleomorphic LCIS (P-LCIS), each characterized by enlarged and 
usually aggregated terminal duct lobular units (TDLUs), filled and distended with neoplastic cells 
3,4,5,6. Necrosis and microcalcifications are often present 3,4,5,6. F-LCIS and P-LCIS are composed of 
different types of cells. In P-LCIS, neoplastic cells are larger than those of C- LCIS, showing marked 
nuclear atypia, and bi- or multinucleated cells are a frequent finding3. P- LCIS should be differentiated 
from high grade ductal in situ carcinoma (DCIS) 3. E-Cadherin is markedly reduced or absent in P-
LCIS and assists the differential diagnosis 3,4,5. 
F-LCIS and P-LCIS are relatively rare and current knowledge of their biological potential is based on 
relatively small series. Data published to present, indicate that these LCIS variants have a close 
relationship with invasive carcinoma. Nevertheless, due to the scarcity of available data, the AJCC 
staging manual 8th Edition, does not categorise F-LCIS and P-LCIS as in situ carcinoma 7,8. Since the 
introduction of the AJCC cancer staging manual 8th Edition, several papers have been published 
focusing on the relation between F-LCIS and P-LCIS and invasive carcinoma, all producing data 
supporting the concept that these variants are high risk lesions 9-14. 
At the present time, the management of screen detected F-LCIS and P-LCIS remains controversial. 
 
The purpose of this study was to evaluate pre-operative biopsy accuracy and cancer underestimation 
in a large multi-institutional series of F- and P- LCIS diagnosed on pre-operative biopsy. Data were 
retrieved in order to evaluate the association between F-LCIS / P-LCIS and invasive carcinoma and 
to evaluate the need for surgery following the diagnosis of these LCIS variants on pre-operative 
biopsy. A literature review is also presented. 
 
 
Materials and methods. 
 
Cases were retrospectively retrieved from 15 European breast units, all involved in breast screening 
programs. Most of the participants are part of the European Working Group on Breast Screening 
Pathology (EWGBSP, http://www.ewgbsp.org/). The Ferrara, Imola and Pisa centres are not part of 
the EWGBSP, but share with the Bologna centre the same diagnostic protocols. 
All the participants agreed on the following definitions of F-LCIS and P-LCIS, established according 
to previously established criteria 1,3,4,5,6. 
Specifically, F-LCIS was diagnosed when it showed: a) markedly expanded ductules or TDLUs 
with little intervening stroma (Fig. 1A); b) neoplastic cells were not cohesive, showing both type A 
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(cells with uniform slightly enlarged nuclei) or type B (cells with larger cytoplasm, more atypical 
nuclei and more prominent nucleoli 1) of morphology (Fig. 1B); c) necrosis was present. 
P-LCIS was diagnosed when it showed: a) markedly expanded ductules or TDLUs with little 
intervening stroma (Fig. 1C); b) the neoplastic cells showed marked atypia, similar to that observed 
in high grade DCIS. In addition, in P-LCIS, bi- or multinucleated neoplastic cells were frequently 
present (fig. 1D). c) necrosis was present. 
All the cases showed lack or marked reduction of E-cadherin immunostaining. 
 
Cases were enrolled in the study when the following criteria were fulfilled: A) F-LCIS and P-LCIS 
presented with screen detected alterations (most often microcalcifications, distortions, dense areas). 
B) Diagnosis was performed on needle core biopsy or vacuum assisted biopsy. C) Pre-operative 
diagnosis was followed by open surgical resection and information on post-surgical histology was 
available. Specifically, surgical excision was offered to all patients after the diagnosis of F/P LCIS. 
Patients who did not receive surgery for co-morbidities or moved to other Breast Units were not 
included in the study. 
In each case, the following parameters were collected: mammographic findings including site(s) of 
biopsy and microcalcification extent where appropriate, association with invasive carcinoma or high 
nuclear grade DCIS in the pre-operative biopsy and / or post-operative specimen. When invasive 
carcinoma was present, the histological type, grade, TNM parameters and biomarker profile were 
recorded. The presence of lympho-vascular invasion (LVI) and peri-neural invasion (PNI) was also 
recorded. 
Pre-operative biopsy underestimation of cancer was defined as an invasive carcinoma or DCIS in the 
excision specimen that was not present on pre-operative biopsy according to Elsheikh and Silverman 
6. 
Pre-operative biopsy accuracy was defined as the ratio between the number of cancers (DCIS and or 
invasive carcinoma) detected on pre-operative biopsy and the total number of cancers. 
 
 
Literature review 
 
A search on PubMed was performed applying the following key words: F-LCIS, P-LCIS, LCIS with 
necrosis, LCIS with calcifications. Papers were considered eligible for the present review  when they 
reported F-LCIS and or P-LCIS diagnosed on pre-operative biopsies followed by surgical excision. 
In several studies that included rare cases of F-LCIS and P-LCIS in large series of C-LCIS, only data 
regarding the F-LCIS and P-LCIS cases were considered. 
 
 
Statistical analyses 
 
All available variables were first compared between the two groups defined as pure F/P-LCIS on pre-
operative biopsies and F/P-LCIS with invasive carcinoma on pre-operative biopsies. 
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The comparisons were made using the Chi-squared test or Fisher exact test for categorical variables 
and with t-test for the continuous variable age. A significance level  equal to 0.05 was considered 
and the p-value reported only if this value was below this predefined level . 
Pre-operative biopsy variables were analysed using logistic regression model only considering pure 
F/P LCIS in biopsy. The outcome variable is represented by the pathological upgrade. As independent 
variables, we considered: microcalcification linear extent, biopsy site (quadrant) and age. 
 
 
Ethical considerations 
 
The present retrospective study did not modify the patients’ treatment and was conducted 
anonymously. The study protocol was approved by the Bologna Ethical Committee (protocol n. 
17181). 
 
 
Results 
 
A total of 117 cases were retrieved, all of which were in adult female patients, aged from 31 to 83 
(average 56.7). Invasive carcinoma and/or DCIS was detected in 78/117 of cases (66.7%). 
Cases were subdivided as follows: 
 
Group A: Pure F/P-LCIS on pre-operative biopsies (n=70). Pathological upgrade in post-surgical 
specimens was observed in 31of 70 cases (44.3%) presenting as pure F/P-LCIS, comprising 28 
invasive carcinomas and 3 cases of DCIS. One case of P-LCIS that remained ‘pure’ after open surgery 
showed positive margins. At the time of surgery, no specific guidelines were available and  a ‘wait 
and see’ policy was adopted. The patient developed invasive lobular carcinoma (ILC) with axillary 
metastasis two years after the initial presentation. Therefore, it was included in the present group, 
among the cases with pathological upgrade. 
Group B: F/P-LCIS with invasive carcinoma on pre-operative biopsies (n=47). 
 
Table 1 summarizes and compares the clinical and pathological features of the two groups. 
 
Pre-operative biopsy accuracy, defined as the ratio between the number of cancers (DCIS and/ or 
invasive carcinoma) detected on pre-operative biopsy and the total number of cancers, was 47/78 
(60.3%). 
Pre-operative biopsy underestimation of cancer, considered as missing an invasive carcinoma or 
DCIS on pre-operative biopsy (as defined by Elsheikh and Silverman6), was 31/78 (39.7%). 
P-LCIS was frequently diagnosed in both groups, with a slight prevalence in Group B, associated 
with invasive carcinoma in pre-operative biopsy. 
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Invasive carcinoma histotype was similar in the two groups, with invasive lobular carcinoma being 
the most frequently diagnosed type. Most of the cases were grade 2 and 3 according to current 
guidelines 15. 
Cases presenting invasive carcinoma in pre-operative biopsies, showed a higher pT category; 
pT2/pT3 cases were 2/28 (7.4%) and 19/41 (47.5%) respectively in Group A and Group B. Similarly, 
LVI and PNI were more common in Group B. Axillary lymph node metastases were similar in the 
two groups (57.1% and 45.5% in Group A and B, respectively. In both groups, most of the invasive 
carcinomas were positive for oestrogen receptor (ER) and progesterone receptor (PR). HER2 
positivity was slightly more frequent in Group B invasive carcinomas. 
Data on mammographic presentation were available in 85 cases. In both groups, microcalcification 
was the most frequent presentation (Group A: 87.1% and Group B: 66.7%). 
Microcalcification linear extent was available in 51 cases for the Group A and in 16 cases for Group 
B and ranged from less than 1 mm to 110 mm. Most cases in both groups showed a limited 
microcalcification extent, being less than 10 mm in 45% of the cases. By multivariate analysis (table 
2), microcalcification extent was the only parameter associated with the risk of pathological upgrade 
in post-operative specimens. Specifically, as seen in table 3, all the cases presenting 
microcalcification linear extent greater than 20mm had invasive carcinoma on post-operative 
specimens. 
Differences between P-LCIS and F-LCIS (table 4). 
 
No differences between P-LCIS and F-LCIS were noted with regard to age and type of presentation. 
Both conditions affected adult female patients, within the same age range, and presented mainly with 
microcalcification. 
When P-LCIS presented in pure form (Group A) on the pre-operative biopsy the risk of subsequent 
pathological upgrade was higher than that observed for F-PLCIS (50% compared with 37.5% 
respectively). In addition, the subsequent pathological upgrade was more frequently to an invasive 
carcinoma for P-LCIS than for F-LCIS (18 invasive carcinomas associated with P-LCIS versus 10 
invasive carcinomas associated with F-LCIS). 
A higher percentage of cases of P-LCIS compared to F-LCIS were in Group B, presenting with an 
associated invasive carcinomas on the pre-operative biopsy (43.3% versus 36% respectively). 
Histotype and grading of the associated invasive carcinoma, did not differ between P-LCIS and F- 
LCIS, as most of the tumours were ILC, grade 2/3. Nevertheless, it should be noted that 10 of the  12 
cases of P-ILC were associated with P-LCIS. Similarly, the pT categories did not differ between the 
two groups, with pT2/pT3 cases constituting 28.9% (13/45) and 33.3% (8/24) of the invasive 
carcinomas associated with P-LCIS and F-LCIS, respectively. Invasive carcinoma associated with P-
LCIS showed more frequent LVI (27.9% vs 8.7%) and PNI (18.6% vs 14.3%) compared with F- 
LCIS, although this difference did not reach statistical significance. In addition, axillary node 
involvement was more frequent in the upgraded P-LCIS group compared to the upgraded F-LCIS 
group (45.5% vs. 30.8% respectively). 
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Hormone receptor profile was similar in the two groups; whereas all of the HER2 positive invasive 
carcinomas were associated with P-LCIS. 
 
 
Literature review. 
 
Nineteen publications met the inclusion criteria for this study (table 5)6, 9-14,16-27. For each paper, only 
those cases of F/P LCIS for which both pre-operative biopsy and post-surgical resection data were 
presented, were retained for review. 
In total, 418 cases of F/P LCIS were eligible. Invasive carcinoma and/or DCIS was present in 181 
cases on pre-operative biopsy and was detected in 93 (of the remaining 237 cases) on post-surgical 
specimens. Therefore, a total of 274/418 (65.5%) cases reported invasive carcinoma and/or DCIS 
associated with F/P LCIS. Pre-operative biopsy accuracy was 66% (181/274) while pre-operative 
biopsy underestimation of cancer was 33.9% (93/274). 
The type and grade of the invasive carcinoma were not reported in all papers. When present, they 
were consistent with those observed in the present series, being composed mainly of invasive lobular 
carcinoma, grade 2/3. 
 
 
Discussion: 
 
F-LCIS and P-LCIS are rare variants of LCIS, the biological nature and significance of which is  still 
debated. Due to the disputed malignant potential of F-LCIS and P-LCIS (AJCC 2018), the present 
multi-institutional study examined the association with carcinoma at the time of diagnosis (pre-
operative or operative). This study, that comprises 117 cases and is the largest reported series to date, 
observed co-existent invasive carcinoma, at the time of diagnosis of these LCIS variants in 78 of 117 
cases (66.7%). Nevertheless, pre-operative biopsy accuracy, defined as the ratio between the number 
of cancers (DCIS and/or invasive carcinoma) detected on pre-operative biopsy and the total number 
of cancers was 47/78 (60.3%). Pre-operative biopsy accuracy was slightly better in the literature 
review, where it reached 66%. Pre-operative biopsy underestimation of cancer, considered as missing 
an invasive carcinoma or DCIS (as defined by Elsheikh and Silverman6), was 39.7%, slightly higher 
than that reported in the literature where it was limited to 33.9%. In spite of minor differences (see 
supplementary materials, table 6, for comparison between the present series and the literature review), 
which are most likely related to the limited number of cases reported and to the lack of uniform 
diagnostic criteria, all of the data collected, from the literature review and from the present series, 
indicate that preoperative biopsy is associated with a high risk of underestimation of carcinoma in F-
LCIS and P-LCIS presenting through mammographic screening programs. 
In the present series, clinical data were analysed in order to identify features that may be predictive 
of a higher risk of associated invasive carcinoma following a diagnosis of pure F-LCIS and P-LCIS 
on pre-operative biopsy. Microcalcification linear extent and the histotype P-LCIS were associated 
with a higher risk of pathological upgrade to carcinoma (DCIS or invasive carcinoma) on surgical 
excision. Microcalcification linear extent greater than 20 mm was always associated with the presence 
of invasive carcinoma in this series. Post-surgical pathological upgrade was also higher for 
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P-L CIS than for F-LCIS (50% vs 37.5%). However, the risk of pathological upgrade is not negligible 
for limited microcalcification linear extent and for F-LCIS. Carcinoma was present in 33.3% of cases 
showing microcalcifications linear extent less than 10 mm and pathological upgrade was observed in 
37.5% of pure F-LCIS cases. The risk of pathological upgrade observed for P- LCIS and F-LCIS 
here, is similar to that observed in cases of high nuclear grade DCIS 28. 
The most frequent type of invasive carcinoma associated with F-LCIS and P-LCIS is ILC, both 
classical and pleomorphic variants. ILC is a diffusely infiltrative tumour, which despite the increased 
sensitivity of modern radiological tools and advances in knowledge, may yield false negative 
mammography in up to 30% of cases 29. ILC may be associated with an aggressive clinical course if 
diagnosed at an advanced stage. It is usually hormone sensitive and prognosis is improved by early 
detection with survival rates of 90% for T1 and T2 tumours 30. The pleomorphic variant of ILC (P-
ILC) is a more aggressive histotype, with higher tendency to local and metastatic spread 
31,32
.  In the present series P-ILC was the second most common histotype detected and it was more 
frequently found in association with P-LCIS (10/12 cases of P-ILC). 
 
Another question often faced during multidisciplinary evaluation of LCIS is the prognostic value of 
resection margin involvement. Currently available knowledge indicates that in cases of C-LCIS a 
‘wait and see’ policy is adequate even in cases with positive resection margins 33. On the contrary, 
very limited data are available on the importance of resection margins involvement by F-LCIS and 
P-LCIS and recurrences 34. In the series published by De Brot et al 35, 4 of 7 patients with positive  or 
close margins developed invasive carcinoma, on average, 54 months (range 46-67) after primary 
surgery. The present series did not include follow-up data. However, one patient, who had positive 
margins after open excision, developed invasive carcinoma with axillary metastases two years after 
primary surgery, suggesting that residual P-LCIS and F-LCIS may be associated with disease 
progression. 
The genetic profile of LCIS has been studied in order to establish the possible relation with ILC. C- 
LCIS and ILC share the same genetic mutations and a clonal relation has been demonstrated 36,37 , 
supporting the concept that C-LCIS is a non-obligate precursor of ILC. P-LCIS and F-LCIS share 
with C-LCIS the same genetic alterations, most commonly recurrent chromosome gains in 1q and 
losses at 16q 38,39 . However P-LCIS and F-LCIS present a higher degree of genomic instability, a 
higher number of DNA copy number modifications and higher gene amplification. The HER2 gene 
is more frequently amplified and p53 gene more frequently mutated in P-LCIS than in C-LCIS5,38. 
Therefore, the molecular data on P-LCIS and F-LCIS indicate that these latter variants of LCIS 
constitute more advanced precursor lesions of invasive carcinoma than C-LCIS. 
In conclusion, the pathological association between P-LCIS and F-LCIS observed in the present series 
and in the literature review strongly supports the concept that these LCIS variants should be regarded 
as high risk precursor lesions of invasive carcinoma. Pre-operative biopsy accuracy in detecting 
carcinoma associated with P-LCIS and F-LCIS varies from 60.3% to 66%, while the risk of 
underestimating the presence of carcinoma ranges from 33.9% to 39.7%. Invasive carcinoma 
associated with P-LCIS and F-LCIS is usually ILC, both classical and P-ILC. The latter is an 
aggressive type of invasive carcinoma that may carry a poor prognosis. On the basis of these data, in 
our opinion, F-LCIS or P-LCIS diagnosed on pre-operative biopsy should be followed by open 
surgical excision for full histological evaluation. The B5a biopsy classification of these entities (in 
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contrast to the B3 classification of C-LCIS and atypical lobular hyperplasia, i.e. classical lobular 
neoplasia) is justified. 2,40 
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 Table 1 
 
 
 
 
 
Table 1: Summary of the cases with comparison between Group A and Group B 
 
 
 
  
Group A 
F/P LCIS 
pure in biopsy 
Group B 
F/P LCS + 
Invasive ca in biopsy 
Total case 
Number 
  
70 
 
47 
Age 
 
57,4 55,7 
(range) (36 – 73) (31 – 83) 
 
Microcalcifications 61/70 24/47 
Presentation Dense area 9/70 12/47 
 NA 0 11/47 
 ≤ 1 mm 10/61 5/24 
 1-10 mm 17/61 6/24 
Microcalcification 10,1-20 mm 14/61 1/24 
linear extent 20,1-30 mm 2/61 1/24 
 > 30 mm 6/61 3/24 
 NA 12/61 8/24 
 
LCIS type 
P 
F 
38 
32 
29 
18 
  
31/70 (44,3%) 
 
Pathological 28 Invasive - 
upgrade carcinoma  
 3 DCIS  
 
DCIS 
 
10/70 
(14,3%) 
3/47 
(6,4%) 
 
ILC 23/28 26/41 
 
Invasive 
carcinoma type 
IC NST 
P-ILC 
Ductal-lobular 
1/28 
 
3/28 
 
12/41 
3/41 
 NA 1/28  
Invasive G1 3/28 1/41 
 carcinoma grade G2 
G3 
NA 
21/28 
3/28 
1/28 
20/41 
19/41 
1/41 
 
T1mi 5/28 2/41 
 T1a 9/28 4/41 
 
Invasive 
carcinoma T size 
T1b 
T1c 
T2 
6/28 
5/28 
2/28 
2/41 
13/41 
14/41 
 T3  5/41 
 NA 1/28 1/41 
 
LVI 
Positive 
NA 
1/28 
2/28 
13/41 
1/41 
 
PNI 
Positive 
NA 
0/28 
4/28 
11/41 
1/41 
 
SN 
Positive 
NA 
6/28 
2/28 
12/40 * 
(30%) 
 
ALN mets 
Positive 
NA 
4/7 
2/28 
5/11 
(45,5%) 
Invasive Positive 24/28 33/47 Positive 
carcinoma ER NA 3/28 9/47 NA 
Invasive Positive 16/28 20/47 Positive 
carcinoma PR NA 4/28 10/47 NA 
Invasive Positive 3/28 7/47 
carcinoma HER-2 NA 4/28 5/47 
Legend: 
LCIS: lobular carcinoma in situ; P: Pleomorphic; F: Florid; N: Number; NA: not available; DCIS; 
Duct carcinoma in situ; ER: Oestrogen Receptor; PR: Progesterone Receptor; HER2 +: HER 2 
evaluated either on immunohistochemistry or on in situ hybridization, according to the ASCO CAP 
guidelines; ILC: invasive lobular carcinoma; IC NST: invasive carcinoma no special type; LVI: 
lymphovascular invasion; PNI: peri-neural invasion; G: grade; Mets: metastases. 
 
* One case underwent ALN dissection without prior SN biopsy. 
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Table 2. Multivariate logistic regression model in F/P LCIS pure in biopsy: 
dependent variable pathological upgrade 
 
-------------------------------------------------------------------------------- 
Pathological upgrade | Odds Ratio [95% Conf. Interval] 
----------------------+--------------------------------------------------------- 
Microcalcif 
Extend 
<=1 (reference) 
1-|10 | .861 .117 6.354 
10-|20 
20-|30 
30.01 + 
Missing 
| 
| 
| 
| 
.530 
omitted 
omitted 
.128 
.062 
 
 
.007 
4.535 
 
 
2.392 
LCIS 
F (reference) 
P. 
 
 
| 
 
 
1.746 
 
 
.405 
 
 
7.530 
Quadrant number 
1 (reference) 
2 or more quadrant 
 
 
| 
 
 
8.683 
 
 
.314 
 
 
240.133 
Quadrant type 
    
External(reference) 
Retroalveoral 
 
| 
 
3.608 
 
.337 
 
38.594 
Other. | .236 .047 1.194 
age | .913 .820 1.016 
Intercept. | 103.782 .116 93175.31 
-------------------------------------------------------------------------------- 
 
note: Microcalfication extent over 20mm predicts pathological upgrade perfectly 
and 11 observation were not been used in the analysis 
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Table 3: Microcalcification linear extent and risk of post-surgical pathological 
upgrade in F/P LCIS pure in biopsy 
 
 
  
Microcalcification 
extent 
 
N. cases 
 
N. pathological 
upgrade 
 
Type of upgrade 
 
≤ 10 mm 
 
28/61 (45.9%) 
 
10/27 (37%) 
8 Invasive ca 
2 DCIS 
 
10 – 20 mm 
 
14/61 (23%) 
 
5/14 (35,7%) 
4 Invasive ca 
1 DCIS 
 
20-30 mm 
 
2/61 (3.3%) 
 
2/2 (100%) 
 
2 Invasive ca 
 
> 30 mm 
 
7/61 (11.5%) 
 
7/7 (100%) 
 
7 Invasive ca 
Linear extent not 
available 
 
10/61 (16.4%) 
 
- 
 
- 
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Table 4: Comparison between P-LCIS and F-LCIS 
 
 
 
P-LCIS F-LCIS 
N of cases 67 50 
Age 56,7 (31-83) 56,7 (36-73) 
 
Presentation 
46 Microcalcifications 
11 Dense area 
10 NA 
39 Microcalcifications 
10 Dense area 
1 NA 
Group A 
Pure LCIS in 
biopsy 
 
 
38/67 
(56,7 %) 
 
 
32/50 
(64%) 
Group B 
Invasive carcinoma 
in biopsy 
 
 
29/67 
(43,3 %) 
 
 
18/50 
(36%) 
 
Pathological 
upgrade 
19/38 (50%) 
18 Invasive carcinoma 
1 DCIS 
12/32 (37,5%) 
10 Invasive carcinoma 
2 DCIS 
DCIS in surgical 
resection 
5/38 (13,2%) 5/32 (15,6%) 
Invasive carcinoma 
in surgical 
resection 
18/38 (47,4%) 10/32 (31,3%) 
 
 
Invasive carcinoma 
type 
28/45 ILC 
10/45 P-ILC 
1/45 IC NST 
5/45 Ductal-lobular 
1/45 NA 
 
21/24 ILC 
2/24 P-ILC 
1/24 Ductal-lobular 
 
Invasive carcinoma 
grade 
1/45 G1 
24/45 G2 
18/45 G3 
3/24 G1 
17/24 G2 
4/24 G3 
  2/45 NA  
 
 
 
 
Invasive carcinoma 
T size 
6/45 T1mi 
9/45 T1a 
6/45 T1b 
10/45 T1c 
10/45 T2 
3/45 T3 
1/45 NA 
1/24 T1mi 
4/24 T1a 
2/24 T1b 
8/24 T1c 
6/24 T2 
2/24 T3 
1/24 NA 
 
LVI 
12/45 Positive 
2/45 NA 
2/24 Positive 
1/24 NA 
 
PNI 
8/45 Positive 
2/45 NA 
3/24 Positive 
3/24 NA 
SN 12/48 Positive (25%)# 6/26 Positive (23,1%)# 
 
ALN mets 
5/11 Positive (45,5%) 
2 NA 
4/13 Positive (30,8%) 
2 NA 
Invasive carcinoma 
ER 
35/46 Positive° (76,1%) 
5 NA 
22/25 Positive° (88%) 
3 NA 
Invasive carcinoma 
PR 
24/46 Positive° (52,2%) 
6 NA 
12/25 Positive° (48%) 
4 NA 
Invasive carcinoma 
HER-2 
amplified** 
10/46 (21,7%) 
4 NA 
0/25 
2 NA 
 
 
Legend: 
LCIS: lobular carcinoma in situ; P: Pleomorphic; F: Florid; N: Number; NA: not available; DCIS; 
Duct carcinoma in situ; ER: Oestrogen Receptor; PR: Progesterone Receptor; HER2 +: HER 2 
evaluated either 3+ on immunohistochemistry or amplified on in situ hybridization, according to  the 
ASCO CAP guidelines; ILC: invasive lobular carcinoma; IC NST: invasive carcinoma no special 
type; LVI: lymph-vascular invasion; PNI: peri-neural invasion; G: grade; SN: sentinel node. 
#  SN  was  examined  in 5 cases (3 P-LCIS and 2 F-LCIS) of pure LCIS, without invasive 
component. 
° Positivity was considered when more than 1% of the neoplastic cells were stained. 
* One case underwent ALN dissection without prior SN biopsy. 
** Difference reaching statistical significance (p 0.011). 
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Table 5: Literature review 
 
 
 
 
Authors 
 
Number 
of P/F 
LCIS 
 
IC in 
pre-op 
bx 
 
DCIS 
in pre- 
op bx 
P/F 
LCIS 
pure 
in pre- 
op bx 
 
 
Path-Up- 
grade 
 
IC 
post- 
op 
 
DCIS- 
post 
op 
 
 
IC type 
Georgian- 
Smith e 
Lawton 16 
 
5 
 
0 
 
0 
 
5 
 
2/5 
 
2 
 
0 
 
ILC 2 
 
Elsheick et al6 
 
2 
 
0 
 
0 
 
2 
 
1/2 
 
1 
 
1 
 
IC NST 1 
Mahoney et 
al17 
 
2 
 
0 
 
0 
 
2 
 
1/2 
 
1 
 
0 
 
ILC 1 
Lavoué et al18 10 0 0 10 3/10 3 0 ILC 3 
Chivukula et 
al19 
 
12 
 
0 
 
0 
 
12 
 
3/12 
 
3 
 
1 
 
ILC 3 
 
Hwang et al20 
 
13 
 
0 
 
0 
 
13 
 
6/13 
 
2 
 
4 
ILC 1 
NA 1 
Carder et al21 10 2 0 8 2/8 3 0 ILC 4 
 
 
Sullivan et 
al22 
 
 
 
28 
 
 
 
0 
 
 
 
0 
 
 
 
28 
 
 
 
10/28 
 
 
 
7 
 
 
 
3 
 
 
 
ILC 7 
Lewis et al23 2 0 0 2 0/2 0 0 / 
 
Niell et al24 
 
4 
 
0 
 
0 
 
4 
 
4/4 
 
3 
 
1 
ILC 2 
IC NST 1 
Flanagan et 
al25 
 
48 
 
22 
 
5 
 
21 
 
11/21 
 
7 
 
4 
ILC 5 
IC DL 2 
Guo et al26 
 
34 
9 
(micro) 
 
0 
 
25 
 
16/25 
 
16 
 
0 
 
ILC 16 
Szynglarewicz 
et al27 
 
5 
 
0 
 
0 
 
5 
 
5/5 
 
5 
 
N.A. 
 
N.A. 
  
Fasola et al9 
 
37 
 
17 
 
20 
 
6/20 
 
4 
 
2 
ILC 3 
P ILC 1 
Savage et al10 15 0 0 15 4/15 2 2 ILC 2 
Desai et al11 15 0 0 15 3/15 3 0 N.A. 
Nakhlis et al12 4 0 0 4 3/4 2 1 N.A. 
 
Shamir et al13 
 
85 
 
56 
 
5 
 
24 
 
5/24 
 
4 
 
1 
ILC 3 
P- ILC 1 
Masannat et 
al14 
 
87 
 
65 
 
22 
 
8/22 
 
7 
 
1 
 
N.A. 
 
 
 
Total 
 
 
 
418 
 
 
 
181 
 
 
 
237 
 
 
 
93/237 
 
 
 
75 
 
 
 
21 
2 N.A. 
ILC 51 
P ILC 2 
IC DL 2 
IC NST 2 
NA 18 
 
 
 
Legend: 
 
DCIS: ductal carcinoma in situ, high grade; LCIS: lobular carcinoma in situ: P: pleomorphic; F: 
Florid; IC: Invasive carcinoma; ILC: invasive lobular carcinoma; IC NST: invasive carcinoma no 
special type; DL: invasive carcinoma mixed type, ductal and lobular; NA: not available. Path: 
pathological; pre-op bx: pre-operative biopsy. 
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Figure legends: 
Figure 1: 
A: At low power, F-LCIS is composed of distended acini filled with neoplastic cells, separated by 
scant stroma. Necrosis is present. 
B: At high power, F-LCIS is composed of type A and B neoplastic cells. 
 
C: At low power, P-LCIS architecture is similar to F LCIS, being composed of closely packed, 
distended acini, filled with neoplastic cells. Necrosis is present. 
D: At high power, P-LCIS is composed of more atypical cells, sometimes bi-nucleated (arrow). 
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